|Bid||16,540.00 x 7100|
|Ask||16,560.00 x 29700|
|Day's Range||15,760.00 - 16,560.00|
|52 Week Range||13,730.00 - 28,300.00|
|Beta (3Y Monthly)||1.40|
|PE Ratio (TTM)||25,915.49|
|Forward Dividend & Yield||2.96 (1.85%)|
|1y Target Est||86.00|
Perrigo Co (NYSE: PRGO) reported second-quarter earnings of 86 cents per share, which beat the analyst consensus estimate of 79 cents by 8.86%. The company reported quarterly sales of $1.127 billion, which missed the analyst consensus estimate of $1.13 billion by 0.27%.
Shares of Perrigo Co. surged 6.0% in premarket trading Thursday, after the over-the-counter health and wellness products company reported second-quarter profit and revenue that beat expectations, and affirmed its full-year outlook. Net income fell to $9 million, or 7 cents a share, from $36 million, or 26 cents a share, in the year-ago period. Excluding non-recurring items, adjusted EPS fell to 86 cents from $1.22, above the FactSet consensus of 79 cents. Sales declined 3.1% to $1.15 billion but topped the FactSet consensus of $1.13 billion, as consumer self-care America sales fell 2.5%, consumer self-care international sales declined 8.5% and prescription pharmaceuticals sales rose 3.4%. The company affirmed its 2019 adjusted EPS outlook of $3.75 to $4.05. The stock has run up 30.3% year to date through Wednesday, while the S&P 500 has gained 15.0%.
DUBLIN , Aug. 8, 2019 /PRNewswire/ -- GAAP ("reported") net sales were $1.15 billion , reflecting a 3% decline versus the prior year period. Non-GAAP ("adjusted") net sales increased ...
TASE: PRGO), a leading provider of "Quality Affordable Self-Care Products™", today announced that Jeffrey C. Smith, Managing Member, Chief Executive Officer, and Chief Investment Officer of Starboard Value LP, who has been a director since 2017, has resigned from Perrigo's Board of Directors effective August 7, 2019. "It is with mixed emotions that I leave the Board of Directors of Perrigo. "We are fortunate to have recruited a world-class leader in Murray Kessler who has quickly assembled an outstanding management team and repositioned Perrigo as a leading self-care company with numerous opportunities for growth and improved efficiency.
Perrigo Co (NYSE: PRGO ) releases its next round of earnings this Thursday, August 8. Get the latest predictions in Benzinga's essential guide to the company's Q2 earnings report. Earnings and Revenue ...
TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.
TASE: PRGO), today announced that it will release its second quarter calendar year 2019 financial results on Thursday, August 8, 2019. The Company will host a conference call beginning at 8 a.m. (EDT).
TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (PETQ) for $185 million. Perrigo CEO and President Murray S. Kessler stated, "Completing the divestiture of the Animal Health business is an important step in the transformation of Perrigo into a consumer-focused self-care company.
EAGLE, Idaho, July 08, 2019 -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced effective today, it has.
TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug Application ("ANDA") referencing Metrogel-Vaginal® (metronidazole vaginal gel 0.75%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days and anticipates launching this product immediately thereafter. The product is manufactured by Perrigo and was developed through its partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. Perrigo Executive Vice President and President Rx Pharmaceuticals, Sharon Kochan stated, "This launch exemplifies Perrigo's commitment to developing and launching products within the extended topicals category.
Perrigo Company (NYSE: PRGO ) has acquired Ranir Global Holdings, a supplier of oral self-care products for $750 million in cash. Perrigo also adjusted its FY2019 earnings guidance, from $3.75-$4.05 including ...
- Advances transformation to a consumer-focused, self-care company - Raises 2019 non-GAAP ("adjusted") diluted EPS guidance to between $3.75 - $4.05 (1), which includes accretion of $0.10 from ...
TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA) referencing Voltaren® Gel, 1% (diclofenac sodium topical gel, 1%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days. Perrigo will manufacture diclofenac sodium topical gel 1% in its plant in Israel.
U.S. stocks fell on Wednesday, as a clutch of weak economic data from the United States and China sparked worries of slowing global growth against the backdrop of a bitter trade dispute that has roiled financial markets. Domestic data showed retail sales unexpectedly fell in April as households cut back on purchases of motor vehicles and a range of other goods, and another report showed declining output of cars and machinery led to a surprise fall in U.S. factory production for April. Meanwhile data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on the country to roll out more stimulus.
Wall Street was set to open lower on Wednesday, as a surprise fall in domestic retail sales and underwhelming data from China raised growth concerns, while investors waited for more developments on the U.S.-China trade dispute. Government data showed U.S. retail sales unexpectedly fell in April as motor vehicle purchases slumped, while data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on Beijing to roll out more stimulus. "The U.S. retail sales report is clearly disappointing.
was gaining more than 5% Thursday after announcing the all-cash acquisition of privately-held Ranir Global Holdings in a deal valued at $750 million. Ranir is the largest private label oral care company in the world, according to Perrigo, with a portfolio of more than 300 oral care products including toothbrush heads and whitening strips. "The addition of Ranir to the Perrigo family illustrates a key component of our new strategy, accelerating growth by pursuing adjacent self-care categories.
Chief Executive Officer and President Murray S. Kessler, along with several key members of his leadership team, will share the Company's strategic plan, vision, and financial objectives while introducing their priorities for transforming Perrigo from a healthcare company to a consumer self-care company. Kessler commented, "We have begun the process of transformation to recapture what we call 'The Perrigo Advantage'. The team has been hard at work during my first six months as CEO, analyzing our challenges and most importantly, building actionable plans to reinvent the company.
Combines Two Consumer-Focused Self-Care Companies Dedicated to Meeting Customer Needs; Expands Ability to Deliver Millions of Affordable Healthy Smiles Worldwide GRAND RAPIDS, Mich. , May 9, 2019 /PRNewswire/ ...
DUBLIN, May 9, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced that it has reached a definitive agreement to purchase privately-held Ranir Global Holdings LLC ("Ranir") in a transaction valued at $750 million on a cash-free, debt-free basis, or approximately $685 million net of cash tax benefits on a present value basis. Ranir is the largest private label oral care company globally, with a comprehensive portfolio of 300+ highly customized oral care solutions including power toothbrush heads, power toothbrush handles, whitening strips, manual toothbrushes, floss, dentures and travel kits that it sells into over 50 countries worldwide.